FLUOROQUINOLONES

Many persons with
Campylobacter infection seek medical care and receive antimicrobial therapy, especially persons with per sistent or bloodstream infection and immunocompromised persons. For persons with severe infection, antimicrobial agents may be life saving. Common antimicrobial agents prescribed for Campylobacter infection are erythromycin, for children, and a fluoroquinolone, such as ciprofloxacin, for adults [11, 12] . Fluoroquinolones have been available in the United States for human use since 1986 and have been shown to reduce the severity and duration of symptoms associated with campylo bacteriosis [13] . Several studies have demonstrated that fluo roquinolone-resistant Campylobacter infections are associated with longer symptoms [14, 15] and more frequent hospitali zations (CDC, unpublished data) than fluoroquinolone-sus ceptible Campylobacter infections.
The US Food and Drug Administration (FDA) licensed 2 fluoroquinolones-sarafloxacin in 1995 and enrofloxacin in 1996-for treatment of respiratory diseases in poultry. Fluo roquinolones used in poultry are added to the drinking water and, thereby, administered on a poultry house-wide basis (to 10,000-30,000 birds). Sarafloxacin-and enrofloxacin-resistant Campylobacter species are also resistant to ciprofloxacin and other fluoroquinolones used in human medicine [8] . Prior to approving fluoroquinolone use in poultry, a FDA joint advisory committee, consisting of members of the FDA's Veterinary Medicine Advisory Committee and Anti-Infective Drugs Ad visory Committee, recommended several conditions for licen sure, including no off label use and the establishment of na tional surveillance of antimicrobial resistance in foodborne bacteria.
FLUOROQUINOLONE-RESISTANT CAMPYLOBACTER SPECIES
To monitor antimicrobial resistance in foodborne pathogens, the CDC, in collaboration with the FDA Center for Veterinary Medicine, the Agricultural Research Service of the US Depart ment of Agriculture, and selected state health departments, launched the National Antimicrobial Resistance Monitoring System (NARMS) [16] . In 1997, NARMS began surveillance for antimicrobial-resistant Campylobacter species in FoodNet sites; in 2004, these sites included Connecticut, Georgia, Mary land, Minnesota, New Mexico, Oregon, and Tennessee and se lected counties in California, Colorado, and New York.
Each week, participating sites selected and forwarded a Cam pylobacter isolate to the CDC for susceptibility testing [17] . Isolates were presumptively identified as Campylobacter species by dark field microscopy and the oxidase test. C. jejuni isolates were further identified using the hippurate hydrolysis test. Hip purate-negative C. jejuni isolates and C. coli isolates were iden tified by PCR [18, 19] . Isolates were then tested for suscepti bility to antimicrobial agents, using the Etest system (AB Biodisk) to determine the MIC for 8 antimicrobial agents (azithromycin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, nalidixic acid, and tetracycline). Campylobacter isolates with a ciprofloxacin MIC �4 mg/mL were considered to be resistant.
Fluoroquinolone-resistant Campylobacter species in humans were first reported in the late 1980s and have been documented in numerous countries [20, 21] . Several investigations have demonstrated that an increased prevalence of fluoroquinolone resistance among human Campylobacter isolates is temporally related to the introduction of fluoroquinolones in veterinary medicine [9, 21, 22] . Fluoroquinolone-resistant Campylobacter species have become increasingly common in the United States. A survey conducted in selected counties by the CDC in 1990 found that none of the 297 human C. jejuni or C. coli isolates tested resistant to ciprofloxacin. In 1999, 18% of human Cam pylobacter isolates submitted to NARMS were fluoroquinolone resistant [9] . Other evidence supports the conclusion that there was little fluoroquinolone resistance among Campylobacter spe cies during the early 1990s in the United States [8, 23, 24] . A study conducted in the University of Pennsylvania Health Sys tem did not identify any fluoroquinolone resistance among C. jejuni isolates recovered from patients during 1982-1992, but 41% of isolates were found to be resistant in 2001 [23, 24] .
The rapid increase in the prevalence of fluoroquinolone re sistance among human Campylobacter isolates was a cause for concern during the late 1990s. To estimate the risk posed to human health by fluoroquinolone-resistant Campylobacter spe cies that were associated with the domestic use of fluoroquin olones in poultry, the FDA Center for Veterinary Medicine developed a quantitative risk assessment model [25] . The model estimated that 153,580 persons were infected with fluoroquin olone-resistant Campylobacter species in 1999 as a result of chicken consumption; 9261 of these persons were estimated to have been treated with a fluoroquinolone. The model also es timated that 1.2 billion pounds of boneless chicken contami nated with fluoroquinolone-resistant Campylobacter species were consumed in the United States during 1999.
PUBLIC HEALTH ACTION
These data, in addition to FoodNet and NARMS data, prompted the FDA to propose withdrawal of the approval of the new animal drug applications for fluoroquinolone use in poultry, an action that would prohibit fluoroquinolone use in chickens and turkeys in the United States [26] . In October 2000, the FDA issued a Notice of Opportunity for Hearing based on evidence that fluoroquinolone use in poultry caused develop ment of fluoroquinolone-resistant Campylobacter species, fluoroquinolone-resistant Campylobacter species were transferred to humans, and fluoroquinolone-resistant Campylobacter in fections were a hazard to human health. Prior to the issuance of this Notice of Opportunity for Hearing, Abbott Laboratories, sponsor of sarafloxacin, requested withdrawal of the new an imal drug application applicable to sarafloxacin, thereby re moving sarafloxacin from the market and making the Notice of Opportunity for Hearing only applicable to enrofloxacin use in poultry. In November 2000, Bayer Corporation, sponsor of enrofloxacin, requested a hearing. In February 2002, the FDA's acting deputy commissioner issued a Notice of Hearing, which granted Bayer a formal hearing and identified subjects of dis cussion for the evidentiary hearing [27] . During May 2004, each participant submitted exceptions, challenging legal and factual points to the administrative law judge's initial decision, and in July 2004, each participant submitted responses to each other's exceptions. After review of the entire record and pro ceedings, the FDA commissioner upheld the administrative law judge's initial decision, ordering that the new animal drug ap plication for enrofloxacin be withdrawn, thereby prohibiting the use of enrofloxacin in poultry (effective in September 2005) [28] . The FDA commissioner's final decision is available on the FDA Web site (http://www.fda.gov/oc/antimicrobial/ baytril.html).
CLINICAL IMPLICATIONS OF REGULATORY ACTION
Although the withdrawal of enrofloxacin for use in poultry in the United States became effective in September 2005, it is unlikely that national surveillance will observe a marked de crease in fluoroquinolone-resistant Campylobacter infection for several years. Studies have shown that fluoroquinolone-resistant Campylobacter species replace the environmental niche once filled by fluoroquinolone-susceptible Campylobacter species and may remain in the environment [29] . There is likely to be continued circulation of fluoroquinolone-resistant Campylo bacter species in poultry flocks. Until fluoroquinolone-suscep tible Campylobacter species reestablish this environmental niche, clinicians will encounter patients with domestically ac quired, fluoroquinolone-resistant Campylobacter infection.
Furthermore, 13% of Campylobacter infections in the United States are a result of international travel; US regulatory actions are not effective internationally. Clinicians are likely to continue to observe persons returning from foreign travel who have acquired a fluoroquinolone-resistant enteric infection while abroad. Foreign travel, especially to southeast Asia, is a doc umented risk factor for fluoroquinolone-resistant enteric in fections, including Campylobacter and Salmonella infections [8, 15, 30, 31] . Fluoroquinolones and other antimicrobial agents continue to be widely used in human and veterinary medicine in other countries. Thus, clinicians should consider travel his tory before empirically treating patients with enteric infections with fluoroquinolones.
The withdrawal of enrofloxacin for use in poultry in the United States may additionally reduce the selective pressure on nontyphoidal Salmonella species and other foodborne patho gens. Nontyphoidal Salmonella isolates with a decreased sus ceptibility to fluoroquinolones rapidly emerged following the approval for enrofloxacin in poultry [32] . When this selective pressure is removed, clinicians may observe a reduction in do mestically acquired, nontyphoidal Salmonella infections that have a decreased susceptibility to fluoroquinolones.
CONCLUSIONS
The decision to withdraw the new animal drug application for enrofloxacin use in poultry was a seminal event, marking the first time an animal drug was removed from the market because of the associated emergence of resistance in humans. These events prompted the FDA to develop an evidence-based ap proach for approving animal antimicrobial drugs that are of clinical importance to humans. Both new animal antimicrobial drugs and those currently approved and marketed will be eval uated using a system that looks at the probability of emerging antimicrobial resistance in animals as a result of drug use, the probability that these resistant bacteria will be transferred to humans, and the probability that these resistant bacteria will adversely affect human health [33] . This new animal drug ap proval system will help preserve the efficacy of antimicrobial agents, such as fluoroquinolones, that are essential to human medicine.
Although improvements to the process for approving new animal antimicrobial drugs have been made, fluoroquinolones and other antimicrobial agents continue to be widely used in human and veterinary medicine. Judicious use of antimicrobial agents should be stressed to preserve the efficacy of these im portant chemotherapeutic agents.
